We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Chevron, Eli Lilly, Charles Schwab, Salesforce and SAP
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 15, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , Eli Lilly and Co. (LLY - Free Report) , The Charles Schwab Corp. (SCHW - Free Report) , Salesforce, Inc. (CRM - Free Report) and SAP SE (SAP - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stocks Reports for Chevron, Eli Lilly and Charles Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp., Eli Lilly and Co. and The Charles Schwab Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Chevron shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+59.6% vs. +47.7%). Based on a slew of tailwinds, the company is poised for further capital appreciation. The supermajor is considered one of the best placed integrated oil firms to achieve sustainable production growth, thanks to its premier position in the lucrative Permian Basin.
Chevron’s Noble Energy takeover expanded its footprint in the region and the DJ Basin along with the addition of cash generating offshore assets in Israel. In shareholder friendly moves, the integrated major recently hiked its dividend and boosted the stock repurchase program.
Considering all of these factors, the Zacks analyst expect the company’s EPS to grow 148% this year. Consequently, Chevron is viewed as a preferred energy major to own now.
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+36.3% vs. +8.0%). The company’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
Lilly expects to launch five new medicines by 2023 end including Mounjaro for type diabetes (already launched) and donanemab for early Alzheimer's disease. Both drugs have multibillion dollar sales potential.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds. Estimates have gone down slightly ahead of Q3 results. Lilly has a negative record of earnings surprises in the recent quarters.
Shares of Charles Schwab have declined -4.3% over the past year against the Zacks Financial - Investment Bank industry’s decline of -9.5%. The company does not have an impressive earnings surprise history. Its elevated expenses might hamper the company's bottom-line growth to an extent. A stretched valuation limits the upside potential of the stock.
However, its earnings surpassed the Zacks Consensus Estimate in two and lagged in two of the trailing four quarters. Strategic acquisitions, likely to be earnings accretive, have reinforced Schwab's position as a leading brokerage player. Offering commission-free trading has led to a rise in client assets and brokerage accounts, thereby improving trading revenues.
The interest rate hikes are expected to aid margin growth. Also, Schwab's efficient capital deployments reflect a solid balance sheet position, through which it will enhance shareholder value.
Other noteworthy reports we are featuring today include Salesforce, Inc. and SAP SE.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Chevron, Eli Lilly, Charles Schwab, Salesforce and SAP
For Immediate Release
Chicago, IL – November 15, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron Corp. (CVX - Free Report) , Eli Lilly and Co. (LLY - Free Report) , The Charles Schwab Corp. (SCHW - Free Report) , Salesforce, Inc. (CRM - Free Report) and SAP SE (SAP - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stocks Reports for Chevron, Eli Lilly and Charles Schwab
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp., Eli Lilly and Co. and The Charles Schwab Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Chevron shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+59.6% vs. +47.7%). Based on a slew of tailwinds, the company is poised for further capital appreciation. The supermajor is considered one of the best placed integrated oil firms to achieve sustainable production growth, thanks to its premier position in the lucrative Permian Basin.
Chevron’s Noble Energy takeover expanded its footprint in the region and the DJ Basin along with the addition of cash generating offshore assets in Israel. In shareholder friendly moves, the integrated major recently hiked its dividend and boosted the stock repurchase program.
Considering all of these factors, the Zacks analyst expect the company’s EPS to grow 148% this year. Consequently, Chevron is viewed as a preferred energy major to own now.
(You can read the full research report on Chevron here >>>)
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+36.3% vs. +8.0%). The company’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
Lilly expects to launch five new medicines by 2023 end including Mounjaro for type diabetes (already launched) and donanemab for early Alzheimer's disease. Both drugs have multibillion dollar sales potential.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds. Estimates have gone down slightly ahead of Q3 results. Lilly has a negative record of earnings surprises in the recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Shares of Charles Schwab have declined -4.3% over the past year against the Zacks Financial - Investment Bank industry’s decline of -9.5%. The company does not have an impressive earnings surprise history. Its elevated expenses might hamper the company's bottom-line growth to an extent. A stretched valuation limits the upside potential of the stock.
However, its earnings surpassed the Zacks Consensus Estimate in two and lagged in two of the trailing four quarters. Strategic acquisitions, likely to be earnings accretive, have reinforced Schwab's position as a leading brokerage player. Offering commission-free trading has led to a rise in client assets and brokerage accounts, thereby improving trading revenues.
The interest rate hikes are expected to aid margin growth. Also, Schwab's efficient capital deployments reflect a solid balance sheet position, through which it will enhance shareholder value.
(You can read the full research report on Charles Schwab here >>>)
Other noteworthy reports we are featuring today include Salesforce, Inc. and SAP SE.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.